REGENXBIO and Biogen enter exclusive license agreement for development of gene therapy treatments for rare genetic vision disorders

Client(s) REGENXBIO Inc.

Jones Day advised REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, in connection with an exclusive worldwide license agreement with Biogen for the development of gene therapy product candidates based on the NAV® Technology Platform for the treatment of two rare genetic vision disorders. The NAV® Technology Platform is an AAV gene delivery platform consisting of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. Under the terms of the agreement, REGENXBIO has granted Biogen an exclusive worldwide license, with rights to sublicense, to REGENXBIO's NAV® AAV8 and AAV9 vectors for the development of gene therapy product candidates for the treatment of two rare genetic vision disorders in humans. Upon selection of a single vector for each indication, the research license will convert to a commercial license. In return for these rights, REGENXBIO will receive an undisclosed upfront payment, ongoing fees, milestone payments and royalties on net sales of products incorporating the licensed intellectual property.